lorglumide has been researched along with Cancer of Gastrointestinal Tract in 1 studies
lorglumide: RN given refers to (+-)-isomer
lorglumide : A racemate comprising equal amounts of (R)- and (S)-lorglumide.
N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watson, SA | 1 |
| Morris, DL | 1 |
| Durrant, LG | 1 |
| Robertson, JF | 1 |
| Hardcastle, JD | 1 |
1 other study available for lorglumide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide.
Topics: Animals; Binding Sites; Gastrins; Gastrointestinal Neoplasms; Octreotide; Proglumide; Rats; Receptor | 1992 |